Literature DB >> 29169524

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib.

Parneet K Cheema1, Mark Doherty2, Ming-Sound Tsao3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29169524     DOI： 10.1016/j.jtho.2017.07.033

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  12 in total

1.  ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation.

Authors:  Frederick H Wilson; Katerina Politi
Journal:  Cancer Discov       Date:  2018-06       Impact factor: 39.397

2.  Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung.

Authors:  Daisuke Ueda; Masaoki Ito; Yasuhiro Tsutani; Ana Giménez-Capitán; Ruth Román-Lladó; Ana Pérez-Rosado; Cristina Aguado; Kei Kushitani; Yoshihiro Miyata; Koji Arihiro; Miguel Angel Molina-Vila; Rafael Rosell; Yukio Takeshima; Morihito Okada
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-01       Impact factor: 4.553

3.  Neuregulin 1 (NRG1) fusion-positive high-grade spindle cell sarcoma: A distinct group of soft tissue tumors with metastatic potential.

Authors:  Josephine K Dermawan; Youran Zou; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2021-11-30       Impact factor: 5.006

Review 4.  New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).

Authors:  Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

5.  PDCD4 limits prooncogenic neuregulin-ErbB signaling.

Authors:  Juan Carlos Montero; Atanasio Pandiella
Journal:  Cell Mol Life Sci       Date:  2020-08-17       Impact factor: 9.261

6.  Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

Authors:  Alexander Drilon; Romel Somwar; Biju P Mangatt; Henrik Edgren; Patrice Desmeules; Anja Ruusulehto; Roger S Smith; Lukas Delasos; Morana Vojnic; Andrew J Plodkowski; Joshua Sabari; Kenneth Ng; Joseph Montecalvo; Jason Chang; Huichun Tai; William W Lockwood; Victor Martinez; Gregory J Riely; Charles M Rudin; Mark G Kris; Maria E Arcila; Christopher Matheny; Ryma Benayed; Natasha Rekhtman; Marc Ladanyi; Gopinath Ganji
Journal:  Cancer Discov       Date:  2018-04-02       Impact factor: 39.397

Review 7.  Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.

Authors:  Kenichi Suda; Tetsuya Mitsudomi
Journal:  Transl Lung Cancer Res       Date:  2020-12

8.  Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.

Authors:  Jacques Cadranel; Stephen V Liu; Michaël Duruisseaux; Eva Branden; Yasushi Goto; Benjamin A Weinberg; Christoph Heining; Richard F Schlenk; Parneet Cheema; Martin R Jones; Alexander Drilon; Domenico Trombetta; Lucia Anna Muscarella; Khaled Tolba; Valerie Gounant; Agnieszka Cseh; Flavio Solca; Janessa J Laskin; Daniel J Renouf
Journal:  Oncologist       Date:  2020-09-23

9.  Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.

Authors:  Alexander Drilon; Michael Duruisseaux; Ji-Youn Han; Masaoki Ito; Christina Falcon; Soo-Ryum Yang; Yonina R Murciano-Goroff; Haiquan Chen; Morihito Okada; Miguel Angel Molina; Marie Wislez; Philippe Brun; Clarisse Dupont; Eva Branden; Giulio Rossi; Alexa Schrock; Siraj Ali; Valérie Gounant; Fanny Magne; Torsten Gerriet Blum; Alison M Schram; Isabelle Monnet; Jin-Yuan Shih; Joshua Sabari; Maurice Pérol; Viola W Zhu; Misako Nagasaka; Robert Doebele; D Ross Camidge; Maria Arcila; Sai-Hong Ignatius Ou; Denis Moro-Sibilot; Rafael Rosell; Lucia Anna Muscarella; Stephen V Liu; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2021-06-02       Impact factor: 50.717

Review 10.  NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.

Authors:  J Laskin; S V Liu; K Tolba; C Heining; R F Schlenk; P Cheema; J Cadranel; M R Jones; A Drilon; A Cseh; S Gyorffy; F Solca; M Duruisseaux
Journal:  Ann Oncol       Date:  2020-09-09       Impact factor: 51.769
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.